Therapy News and Research

RSS

PPMD to fund two promising research initiatives in Duchenne muscular dystrophy

Patricia A. Furlong, Founding President and CEO of Parent Project Muscular Dystrophy (PPMD), the largest non-profit organization in the United States focused on finding a cure for Duchenne muscular dystrophy (Duchenne), announced today that PPMD will be funding two critical, promising research initiatives in Duchenne.

11 Jun 2010

APTA accredits Fox Rehabilitation to offer post-graduate residency training program in geriatrics

The American Physical Therapy Association has accredited Fox Rehabilitation to offer a new, post-graduate residency training program exclusively in geriatrics. Fox Rehabilitation is the only private physical therapy practice in the nation to receive this prestigious designation.

11 Jun 2010

Botox reduces short-term pain in thoracic outlet syndrome patients

Made popular for its ability to smooth wrinkles when injected into the face, Botox - a toxin known to weaken or paralyze certain nerves and muscles - may have another use that goes beyond the cosmetic.

11 Jun 2010

AFREZZA non-inferior to standard therapy insulin lispro in reducing HbA1c levels of Type 1 diabetics

MannKind Corporation today announced that results of a new 16-week trial show that the investigational ultra rapid acting mealtime insulin, AFREZZA™ (insulin human [rDNA origin]) Inhalation Powder, combined with basal insulin, is clearly non-inferior to standard therapy insulin lispro, a rapid acting insulin, also combined with basal insulin, in reducing HbA1c levels in subjects with inadequately controlled Type 1 diabetes.

11 Jun 2010

Shenzhen Beike Biotechnology forms joint venture with SiriCell Technologies

Shenzhen Beike Biotechnology Co. Ltd., China's leading stem cell research and regenerative medicine company, announced the formation of Beike Holdings Limited a joint venture with Bangkok-based SiriCell Technologies, Inc. Beike Holdings, which is headquartered in Bangkok, Thailand, will focus primarily on the establishment of new international subsidiaries and the development of collaborative hospital partnerships with Southeast Asia's leading healthcare providers.

11 Jun 2010

Phase 3 AVERROES clinical trial of apixaban for atrial fibrillation closes early due to clear evidence of efficacy

Bristol-Myers Squibb Company and Pfizer today announced that the companies have agreed to stop the Phase 3 AVERROES clinical trial of apixaban in patients with atrial fibrillation. The study will be stopped early because a predefined interim analysis by the independent Data Monitoring Committee (DMC) revealed clear evidence of a clinically important reduction in stroke and systemic embolism in patients with atrial fibrillation considered intolerant of or unsuitable for vitamin K antagonist therapy who received apixaban as compared to aspirin.

11 Jun 2010

FDA advisory committee recommends approval of Novartis' FTY720 for relapsing MS

Today, an advisory committee of the US Food and Drug Administration (FDA) recommended approval of FTY720 (fingolimod) for the treatment of patients with relapsing multiple sclerosis, the most common form of the disease. The FDA has the option of seeking the advice of one of its advisory committees as it reviews and decides whether to approve a new treatment. The committee voted unanimously that FTY720 demonstrated substantial efficacy in treating relapsing remitting MS and that safety of the proposed 0.5 mg dose justified approval.

11 Jun 2010

22 Midwest facilities named Centers of Excellence in accelerated partial breast irradiation

Twenty-two facilities in the Midwest have been named Centers of Excellence in accelerated partial breast irradiation (APBI) for their use of the SAVI® applicator, an advanced therapy for breast cancer as part of breast conservation therapy. The SAVI applicator can provide important advantages for women with early-stage breast cancer.

10 Jun 2010

Onset Therapeutics expands sales force by over 50% in 2010

Onset Therapeutics, a specialty pharmaceutical company focused in dermatology, today announced the completion of the Company's latest sales force expansion initiative designed to provide national dermatology coverage to support the success of two recently launched products and the Company's rapidly growing pipeline of products in various stages of development.

10 Jun 2010

MAP Pharmaceuticals to present new analyses from LEVADEX Phase 3 trial for acute migraine at 52nd AHS

MAP Pharmaceuticals, Inc. today announced that the Company will present new analyses from the FREEDOM-301 Phase 3 trial of its investigational LEVADEX™ orally inhaled migraine therapy. The post hoc analyses will be presented at the 52nd Annual Scientific Meeting of the American Headache Society (AHS) in Los Angeles, California.

10 Jun 2010

Extensive usage of antibiotic linezolid associated with ICU outbreak of LRSA

An outbreak of infection due to linezolid and methicillin-resistant Staphylococcus aureus (LRSA) in 12 intensive care unit patients in Spain was associated with transmission within the hospital and extensive usage of the antibiotic linezolid, often used for the treatment of serious infections, with reductions in linezolid use and infection-control measures associated with resolution of the outbreak, according to a study in the June 9 issue of JAMA.

10 Jun 2010

Brain stimulation with ultrasound may enhance cognitive function

The ability to diagnose and treat brain dysfunction without surgery, may rely on a new method of noninvasive brain stimulation using pulsed ultrasound developed by a team of scientists led by William "Jamie" Tyler, a neuroscientist at Arizona State University. The approach, published in the journal Neuron on June 9, shows that pulsed ultrasound not only stimulates action potentials in intact motor cortex in mice but it also "elicits motor responses comparable to those only previously achieved with implanted electrodes and related techniques," says Yusuf Tufail, the lead author from ASU's School of Life Sciences.

10 Jun 2010

Allopurinol exhibits potential benefits for CKD patients

A drug commonly used to treat gout may help maintain kidney disease patients' health, according to an analysis appearing in an upcoming issue of the Clinical Journal of the American Society of Nephrology (CJASN). The research is the first to show that allopurinol treatment in patients with chronic kidney disease (CKD) decreases inflammation, slows the progression of kidney disease, and reduces patients' risk of experiencing a cardiovascular event or being hospitalized.

10 Jun 2010

Human Genome Sciences submits BLA for BENLYSTA to FDA

Human Genome Sciences, Inc. today announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for approval to market BENLYSTA® (belimumab) for the treatment of systemic lupus erythematosus (SLE).

10 Jun 2010

New study finds propofol poses low risk for children undergoing research-driven imaging studies

A new study finds that propofol, a well-known anesthesia medication, has a low occurrence of adverse events for children undergoing research-driven imaging studies. The study, led by a pediatric anesthesiologist now at Children's National Medical Center, showed a low incidence of adverse events and no long term complications when propofol was used to sedate children for imaging studies that require them to be still for long periods of time.

10 Jun 2010

Aeterna Zentaris reports final results on clinical activity of perifosine for metastatic colorectal cancer

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today reported final results on the clinical activity of perifosine (KRX-0401), the Company's novel, potentially first-in-class, oral anticancer agent that inhibits Akt activation in the phosphoinositide 3-kinase pathway, in combination with capecitabine (Xeloda) as a treatment for advanced, metastatic colorectal cancer.

10 Jun 2010

DermaGenoma releases CelluliteDX Genetic Test for women

As summer swimsuit season heats up, women around the world will inspect their looks in the mirror. A majority of them will see cellulite - at some point - but a new genetic test may be able to help them avoid cellulite before anyone notices.

10 Jun 2010

Therapies for female sexual dysfunction

Many women experience problems in the bedroom at one time or another. Female sexual dysfunction is not uncommon and although some women and healthcare providers have difficulty discussing it, it has been recognized by the medical community for decades. In fact, for the last twenty years, it has been listed in the Diagnostic and Statistical Manual of Mental Disorders, a manual published by the American Psychiatric Association, used to classify and diagnose psychological disorders.

10 Jun 2010

Effectiveness of combination band ligation and nadolol for first variceal bleeding not established

A controlled trial conducted by researchers at the E-DA Hospital in Kaohsiung, Taiwan, suggests that a combination of band ligation and nadolol may not be the most effective prophylaxis for first variceal bleeding resulting from cirrhosis. Results of this study appear in the July issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases (AASLD).

10 Jun 2010

Mutations in ion channels cause rare inherited pain disorder: Research

A mutation that enhances the function of a specific ion channel has been identified as the cause of a rare inherited pain disorder. The research, published by Cell Press in the June 10 issue of the journal Neuron, proposes a potential treatment for the disorder and may lead to a better understanding of chronic pain in humans.

10 Jun 2010

Therapy News and Research

PPMD to fund two promising research initiatives in Duchenne muscular dystrophy

APTA accredits Fox Rehabilitation to offer post-graduate residency training program in geriatrics

Botox reduces short-term pain in thoracic outlet syndrome patients

AFREZZA non-inferior to standard therapy insulin lispro in reducing HbA1c levels of Type 1 diabetics

Shenzhen Beike Biotechnology forms joint venture with SiriCell Technologies

Phase 3 AVERROES clinical trial of apixaban for atrial fibrillation closes early due to clear evidence of efficacy

FDA advisory committee recommends approval of Novartis' FTY720 for relapsing MS

22 Midwest facilities named Centers of Excellence in accelerated partial breast irradiation

Onset Therapeutics expands sales force by over 50% in 2010

MAP Pharmaceuticals to present new analyses from LEVADEX Phase 3 trial for acute migraine at 52nd AHS

Extensive usage of antibiotic linezolid associated with ICU outbreak of LRSA

Brain stimulation with ultrasound may enhance cognitive function

Allopurinol exhibits potential benefits for CKD patients

Human Genome Sciences submits BLA for BENLYSTA to FDA

New study finds propofol poses low risk for children undergoing research-driven imaging studies

Aeterna Zentaris reports final results on clinical activity of perifosine for metastatic colorectal cancer

DermaGenoma releases CelluliteDX Genetic Test for women

Therapies for female sexual dysfunction

Effectiveness of combination band ligation and nadolol for first variceal bleeding not established

Mutations in ion channels cause rare inherited pain disorder: Research

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News